Form 4: Agenus Inc. Director Brian Corvese Reports Stock Option Award

Director Brian Corvese reports the acquisition of stock options in Agenus Inc. on February 5, 2024.

Summary

• Brian Corvese, a director of Agenus Inc., reported the acquisition of 15,000 stock options on February 5, 2024.
• The stock options have an exercise price of $12.60 and will vest on February 5, 2025.
• The options expire on February 5, 2034.
• These options were granted under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan.
• The stock options were granted prior to the 1 for 20 reverse stock split, representing 300,000 Stock Options with an exercise price of $0.63.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing regarding stock option grants, with no inherent positive or negative sentiment.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to improve company performance, benefiting shareholders.

Key Dates